Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting a non-interventional, observational study to understand the long-term use of dupilumab in treating eosinophilic esophagitis EoE among patients aged 12 years and older in Germany. The study aims to describe patients medical history, socio-demographic and disease characteristics, related conditions, prior therapies, and the real-world patterns of dupilumab treatment. It also seeks to assess long-term effectiveness and safety of dupilumab, along with its impact on patients quality of life over two years. Participants in this study are those receiving dupilumab for EoE in routine clinical settings without any treatment intervention from the study team. The observational period for each participant is planned to last approximately two years, during which data on dupilumab use and safety will be collected continuously. This includes tracking treatment details, symptom changes, and any adverse events as reported by physicians and patients. Throughout the study, participants will have their medical, socio-demographic, and disease data analyzed at baseline. Follow-up assessments will record changes in endoscopic scores, esophageal biopsy results, clinical symptoms, food intake behavior, and various quality of life and symptom scales at multiple time points over two years. Hospitalization and sick leave data related to EoE will also be monitored. Safety data will be collected throughout the treatment period to better understand dupilumabs long-term use in real-world practice.
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.
Actively Recruiting
Researchers are studying targeted therapies for adults with moderately to severely active Rheumatoid Arthritis RA, a chronic condition causing joint pain, stiffness, swelling, and loss of function. This Phase 2 trial aims to evaluate the safety and effectiveness of three different treatment approaches compared to placebo in participants who have not responded well to one or two prior biologic or targeted synthetic disease-modifying antirheumatic drugs btsDMARDs. The study includes three substudies Lutikizumab monotherapy versus placebo, Ravagalimab monotherapy versus placebo, and a combination of Lutikizumab and Ravagalimab versus placebo. Treatments are given as subcutaneous injections with participants randomized to receive either active drugs or matching placebo doses. Approximately 180 participants will enroll and receive study treatments during the trial. Participants will have regular visits at hospitals or clinics where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted. The main outcomes measured include the percentage of participants achieving significant improvement in RA symptoms American College of Rheumatology 50% response at 12 weeks and tracking adverse events up to about 22 weeks. The study continues until November 2027 with ongoing safety and efficacy monitoring.
Actively Recruiting
Researchers are evaluating bimekizumab administered intravenously compared to subcutaneous injection in adults with active psoriatic arthritis or active axial spondyloarthritis. The study aims to show that the intravenous method is not less effective than the subcutaneous method by assessing how the drug moves in the body over time. This is a Phase 1, open-label, randomized, parallel-group study focused on treatment. Participants will receive one of three dosing regimens of bimekizumab during a pharmacokinetics lead-in phase and continue with the same assigned regimen during the treatment period. The dosing regimens include intravenous and subcutaneous administration of bimekizumab at specified times. Subjects are randomized into one of two experimental arms reflecting different intravenous regimens or a third arm receiving the subcutaneous regimen. During the study, participants will be monitored for steady-state trough concentration of the drug at week 16. Safety is assessed by tracking treatment-emergent adverse events, serious adverse events, and any events leading to withdrawal from the study through week 29. The study duration extends to the end of safety follow-up, with regular assessments to evaluate drug levels and participant health under medical supervision.
Actively Recruiting
Psoriatic arthritis PsA is a type of arthritis that causes joint swelling and stiffness, often occurring in people with the skin condition psoriasis. This study aims to understand how long patients continue treatment and how effective risankizumab RZB is compared to other advanced treatments for PsA in everyday clinical settings. The study will take place outside the United States across about 15 countries, involving between 900 and 1200 adult participants. Participants will receive either risankizumab or other biologic disease-modifying antirheumatic drugs bDMARDs as prescribed by their doctors following local guidelines. Treatments will be given as part of regular medical care without additional interventions from the study. Participants will be followed and observed for 24 months during their routine clinical visits. During the study, participants will attend their usual medical appointments where doctors will monitor their treatment persistence and response. The main outcome measured is how many participants continue their prescribed treatment up to 24 months. There is no expected extra burden or additional procedures for participants beyond their standard care.
Actively Recruiting
Researchers are evaluating real-world clinical and patient-reported outcomes in adults with systemic lupus erythematosus SLE who are starting subcutaneous anifrolumab treatment for the first time. This prospective, single-arm, multicenter non-interventional study aims to describe key treatment goals such as remission DORIS and low disease activity LLDAS, quality of life, medication patterns, flares, and organ damage in routine care. Participants will be observed over a 24-month period while receiving subcutaneous anifrolumab as prescribed in routine clinical practice, following the applicable European summary of product characteristics. The study does not intervene in treatment decisions but collects information on disease activity, medication use, and clinical outcomes during this time. During the 24 months, data will be collected from routine visits including assessments of disease activity indices, patient questionnaires on fatigue and quality of life, and monitoring of flares and organ damage. Researchers will measure outcomes such as the proportion of patients achieving remission at 24 months and changes in disease activity scores, aiming to capture long-term disease control and treatment patterns.
Actively Recruiting
Researchers are investigating the effects of additional chemotherapy treatment after surgery or ablation in patients with metastatic colorectal cancer whose tumor lesions have been definitively treated. This phase III, open-label, randomized, controlled trial aims to compare the effectiveness, quality of life, and safety of mFOLFOXIRImFOLFOX-6 chemotherapy against active follow-up without additional chemotherapy. The study also includes a translational research component to analyze tumor biopsies and blood samples for disease relapse markers. Patients are assigned randomly in a 21 ratio to receive either active chemotherapy mFOLFOXIRI, mFOLFOX6, FOLFIRI, or CAPOX for up to six months or structured follow-up without chemotherapy. Chemotherapy regimens involve intravenous infusions and oral medications administered in cycles every two or three weeks, with a maximum of 12 cycles for most treatments. After treatment or follow-up, participants continue with structured monitoring for up to five years. Participants undergo re-assessments every three months during the first two years, including CT or MRI scans of the thorax and abdomen, blood tests, and quality of life evaluations to detect disease relapse. After two years without relapse, follow-up intervals extend to every six months. The primary outcome measured is progression-free survival at 24 months, with secondary outcomes including overall survival, lesion control, adverse events, and quality of life monitored for up to five years following randomization.
Actively Recruiting
Researchers are studying patients with breast cancer, focusing on those with metastatic disease who typically have the poorest outlook. The trial aims to improve treatment decisions and quality of care by analyzing tumor characteristics. Although national guidelines recommend molecular reassessment of metastatic tumors, biopsies are rare due to invasiveness, so the study explores blood-based methods to assess tumor features and their relation to treatment outcomes and health economics. The study involves two groups about 3,500 patients with locally advanced or metastatic breast cancer receiving any line of treatment, and approximately 10,000 patients with early breast cancer undergoing neoadjuvant or adjuvant therapy regardless of regimen. Blood samples will be collected during routine blood draws to analyze tumor molecular characteristics and biomarkers for progression and survival. Participants will be followed with assessments including quality of life, therapy adherence, depression factors, and adverse events at study entry and regularly up to 60 months. The study will measure progression-free survival in metastatic breast cancer and disease-free survival in early breast cancer, along with overall survival and health economic outcomes. Results of molecular testing will be shared with patients at study end, providing comprehensive data to support improved breast cancer care.
Actively Recruiting
Researchers are conducting a prospective registry study to observe and document the treatment and disease progression in patients with recurrent and metastatic prostate cancer. The study includes four distinct patient groups based on disease status those with biochemical recurrence after local treatment, non-metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer. Each group is enrolled and followed independently over different time periods to understand the course of therapy and disease. The study does not prescribe any specific treatment but records routine care as decided by each patients physician. Data collection occurs during routine clinical visits at set intervals, including after enrollment, every 3 to 6 months, and when therapy changes occur. Standardized quality of life questionnaires FACT-P and EQ-5D-5L are completed, and biological samples are collected to support comprehensive assessment. Participants are followed long-term, with an average follow-up of seven years. Researchers document therapy patterns, disease management strategies, imaging assessments, patient-reported outcomes, treatment adherence, and adverse events throughout this period. The focus is on real-world data reflecting everyday clinical practice, enabling a detailed understanding of treatment effectiveness and disease progression in prostate cancer patients.